Synageva BioPharma Corp. (GEVA) reported first quarter 2014 loss of $1.16 per share, wider than the year-ago loss of 54 cents per share, but narrower than the Zacks Consensus Estimate of a loss of $1.19 per share.
First quarter revenues decreased 69.1% from the year-ago quarter to $1.6 million, missing the Zacks Consensus Estimate of $2 million.
In the reported quarter, Synageva earned royalties from Roche (RHHBY) on Fuzeon and collaboration and license revenues from its partners.
R&D expenses increased 108.9% year over year to $27.9 million. SG&A expenses increased 73.4% year over year to $9.8 million.
Synageva’s lead candidate, sebelipase alfa, is in a phase III study (ARIS) for the treatment of lysosomal acid lipase deficiency (LAL deficiency) in children and adults. The company continues to expect top-line results from the study in the third quarter of 2014. By the end of the first quarter of 2015, Synageva expects to file a Biologic License Application (:BLA) for sebelipase alfa for this indication to the U.S. Food and Drug Administration (:FDA) and a marketing authorization application (MAA) to the European Medicines Agency (EMA.TO).
Meanwhile, the company intends to initiate a study on SBC-103 by mid-2014. SBC-103 will be evaluated as an enzyme replacement therapy for mucopolysaccharidosis type IIIB (MPS IIIB). SBC-103 has orphan drug status in the U.S. and the EU.
2014 Guidance Maintained
Synageva expects net operating loss in the range of $190 million to $205 million in 2014. The company continues to invest in its pipeline and expand its global, commercial and medical infrastructure.
Synageva currently carries a Zacks Rank #4 (Sell). We expect investor focus to remain on data from the ARISE study.Read the Full Research Report on RHHBY
Read the Full Research Report on ALXN
Read the Full Research Report on GILD
Read the Full Research Report on GEVA
Zacks Investment Research
- Health Care Industry